Jun 13, 2014 by Nathaniel CallowayWhy I'm Avoiding Taro PharmaceuticalsWhat could be wrong with 5 years of double digit growth with no end in sight? Well, someone else wants it more than you and has a history of not paying full price.
Jun 12, 2014 by Nathaniel Calloway3 Reasons to Watch Array Biopharma Inc.Seldom are the risks or the profit potential higher than investing in small-cap biotech. Here we examine what Array Biopharma is doing that other biotech companies aren't that's getting the attention of the biggest analysts in the business.
May 28, 2014 by Nathaniel CallowayNew FDA Regulations Could Open The Market For Generics of the World's Bestselling BiologicsIts not a coincidence that a majority of the world's bestselling drugs are biologics. These new therapies gained prominence in the past decade in part because they provide increased protection against competition. The FDA hopes to change that by implementing a new fast track for approval for so called biosimilar generics.
May 27, 2014 by Nathaniel CallowayWith the Pfizer-AstraZeneca Deal Dead, Is Pfizer a Buy?The botched merger to create the world's largest pharmaceutical company has left many with a bad taste in their mouth and Pfizer's stock depressed. Will Pfizer return to its plan to divide the company from 2013 and what would this mean for the bottom line? Is now the time to buy?
May 20, 2014 by Nathaniel CallowayCan New CDC Guidelines Help Gilead's Growth?After the blockbuster earnings for Gilead's new hepatitis C drug this past quarter, it's easy to forget that its HIV medication Truvada has been the historical money maker. Now the CDC is advising doctors to prescribe Truvada to anyone at risk of getting HIV, or upwards of half a million Americans.
